Inactive Instrument

News Sorrento Therapeutics, Inc. Deutsche Boerse AG

Equities

8STN

US83587F2020

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ninth Circuit Rules That Biopharmaceutical Company's Announcement Of COVID-19 "Cure" Did Not Violate Securities Laws	05-10	AQ
Ninth Circuit Affirms Dismissal Of Putative Securities Class Action Against Biopharmaceutical Company Over Statements It Had Developed A COVID "Cure"	04-15	AQ
Sorrento Therapeutics, Inc. Emerged from Bankruptcy	04-10	CI
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend	03-27	AQ
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	03-15	MT
Final DIP Financing Approved for Sorrento Therapeutics, Inc.	03-12	CI
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.	03-11	CI
Motion for Asset Sale Approved for Sorrento Therapeutics, Inc.	03-07	CI
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024	03-02	AQ
Interim DIP Financing Approved for Sorrento Therapeutics, Inc.	02-29	CI
Health Care Slips on Growth Doubts -- Health Care Roundup	02-26	DJ
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc.	02-08	CI
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	02-04	CI
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	12-17	CI
Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc.	11-30	CI
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90	11-07	CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Chief Financial Officer	11-07	CI
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President	11-07	CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	11-02	CI
Motion for Asset Sale Filed by Sorrento Therapeutics, Inc.	23-10-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sorrento Therapeutics, Inc. Deutsche Boerse AG

Equities

8STN

US83587F2020

Summary

Filters